9,798 reports of this reaction
2.5% of all INSULIN GLARGINE reports
#5 most reported adverse reaction
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is the #5 most commonly reported adverse reaction for INSULIN GLARGINE, manufactured by sanofi-aventis U.S. LLC. There are 9,798 FDA adverse event reports linking INSULIN GLARGINE to INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION. This represents approximately 2.5% of all 399,332 adverse event reports for this drug.
Patients taking INSULIN GLARGINE who experience inappropriate schedule of product administration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION is a less commonly reported adverse event for INSULIN GLARGINE, but still significant enough to appear in the safety profile.
In addition to inappropriate schedule of product administration, the following adverse reactions have been reported for INSULIN GLARGINE:
The following drugs have also been linked to inappropriate schedule of product administration in FDA adverse event reports:
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION has been reported as an adverse event in 9,798 FDA reports for INSULIN GLARGINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION accounts for approximately 2.5% of all adverse event reports for INSULIN GLARGINE, making it a notable side effect.
If you experience inappropriate schedule of product administration while taking INSULIN GLARGINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.